Now If efti shows mono therapy activity in INSIGHT, the timeline to becoming a midsize market cap is dramatically accelerated. Say companion diagnostic guided treatment 20% of a type of solid tumor pans out, all Prima Biomed old timers will quickly be rewarded for hanging in there. I agree the CEO speaks as if he’s confident in upcoming data. I suppose he’s supposed to do that, but something just might be brewing that hasn’t been unleashed to the market yet.
Now If efti shows mono therapy activity in INSIGHT, the timeline...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.020(7.02%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 29.0¢ | $1.171M | 3.900M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 101067 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 8068 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
